Development, production and testing of novel glycoconjugate pig vaccines

饲养健康的牲畜对经济和社会繁荣至关重要。我们建议利用突破性的技术来生产低成本的糖结合疫苗，以预防三种主要的猪疾病(猪胸膜肺炎、格拉斯病和猪链球菌脑膜炎)，目前的疫苗不能令人满意。我们已经开发了在大肠杆菌细胞中产生克隆糖结合物的技术，这些细胞充当微型工厂，生产取之不尽、可再生的纯疫苗供应。由于生产成本的原因，传统的化学合成的糖结合疫苗尚未用于动物，但在人类身上有着良好的记录，已使用了超过10亿剂。通过LSHTM业务发展办公室和行业合作伙伴，我们将开发、生产和测试针对三大猪呼吸道疾病的新疫苗。一家名为ArcVax的新公司将被剥离出来，以进一步开发这项技术并将疫苗产品商业化。

Healthily maintained livestock are essential for economic and societal prosperity. We propose to exploit ground-breaking technology to produce low cost glycoconjugate vaccines to protect against three major pig diseases (porcine pleuropneumonia, Glässer's disease and S. suis-induced meningitis), where current vaccines are unsatisfactory. We have developed technology to generate cloned glycoconjugates in E. coli cells that act as mini factories to produce an inexhaustible and renewal supply of pure vaccine. Due to production costs, conventional chemically synthesised glycoconjugate vaccines have not been used for animals, but have an excellent track record in humans, where over a billion doses have been used. Through the LSHTM business development office and industrial collaborators we will develop, produce and test new vaccines against the three major pig respiratory diseases. A new company, ArcVax, will be spun-out to further develop the technology and commercialise vaccine product.